JP2020531048A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020531048A5 JP2020531048A5 JP2020530735A JP2020530735A JP2020531048A5 JP 2020531048 A5 JP2020531048 A5 JP 2020531048A5 JP 2020530735 A JP2020530735 A JP 2020530735A JP 2020530735 A JP2020530735 A JP 2020530735A JP 2020531048 A5 JP2020531048 A5 JP 2020531048A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- hcdr3
- lcdr2
- lcdr1
- lcdr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 31
- 239000000427 antigen Substances 0.000 claims 28
- 102000036639 antigens Human genes 0.000 claims 28
- 108091007433 antigens Proteins 0.000 claims 28
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 150000001413 amino acids Chemical class 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 238000004519 manufacturing process Methods 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 5
- 102000044459 human CD47 Human genes 0.000 claims 5
- 229940127121 immunoconjugate Drugs 0.000 claims 5
- 241000282567 Macaca fascicularis Species 0.000 claims 4
- 208000029078 coronary artery disease Diseases 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000003176 fibrotic effect Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 2
- 208000026758 coronary atherosclerosis Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 210000004602 germ cell Anatomy 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- NIZKGBJVCMRDKO-KWQFWETISA-N Ala-Gly-Tyr Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NIZKGBJVCMRDKO-KWQFWETISA-N 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 241000282693 Cercopithecidae Species 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000003807 Graves Disease Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 101000989062 Homo sapiens Immunoglobulin heavy variable 5-51 Proteins 0.000 claims 1
- 101001047627 Homo sapiens Immunoglobulin kappa variable 2-28 Proteins 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 102100029414 Immunoglobulin heavy variable 5-51 Human genes 0.000 claims 1
- 102100022950 Immunoglobulin kappa variable 2-28 Human genes 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims 1
- 206010034811 Pharyngeal cancer Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 201000005188 adrenal gland cancer Diseases 0.000 claims 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000009036 biliary tract cancer Diseases 0.000 claims 1
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 210000000133 brain stem Anatomy 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 230000009615 deamination Effects 0.000 claims 1
- 238000006481 deamination reaction Methods 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 238000013467 fragmentation Methods 0.000 claims 1
- 238000006062 fragmentation reaction Methods 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 238000006317 isomerization reaction Methods 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 238000002703 mutagenesis Methods 0.000 claims 1
- 231100000350 mutagenesis Toxicity 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000029255 peripheral nervous system cancer Diseases 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 230000004481 post-translational protein modification Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023049983A JP7564274B2 (ja) | 2017-08-18 | 2023-03-27 | 結合剤 |
| JP2024167571A JP2025000787A (ja) | 2017-08-18 | 2024-09-26 | 結合剤 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1713298.6A GB201713298D0 (en) | 2017-08-18 | 2017-08-18 | Binding agents |
| GB1713298.6 | 2017-08-18 | ||
| GB1802595.7 | 2018-02-16 | ||
| GBGB1802595.7A GB201802595D0 (en) | 2018-02-16 | 2018-02-16 | Binding agents |
| GBGB1808570.4A GB201808570D0 (en) | 2018-05-24 | 2018-05-24 | Binding agents |
| GB1808570.4 | 2018-05-24 | ||
| PCT/GB2018/052347 WO2019034895A1 (en) | 2017-08-18 | 2018-08-17 | LIAISON AGENTS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023049983A Division JP7564274B2 (ja) | 2017-08-18 | 2023-03-27 | 結合剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020531048A JP2020531048A (ja) | 2020-11-05 |
| JP2020531048A5 true JP2020531048A5 (OSRAM) | 2021-09-30 |
| JP7256580B2 JP7256580B2 (ja) | 2023-04-12 |
Family
ID=63371721
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020530735A Active JP7256580B2 (ja) | 2017-08-18 | 2018-08-17 | 結合剤 |
| JP2023049983A Active JP7564274B2 (ja) | 2017-08-18 | 2023-03-27 | 結合剤 |
| JP2024167571A Pending JP2025000787A (ja) | 2017-08-18 | 2024-09-26 | 結合剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023049983A Active JP7564274B2 (ja) | 2017-08-18 | 2023-03-27 | 結合剤 |
| JP2024167571A Pending JP2025000787A (ja) | 2017-08-18 | 2024-09-26 | 結合剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US10683350B2 (OSRAM) |
| EP (2) | EP4435008A2 (OSRAM) |
| JP (3) | JP7256580B2 (OSRAM) |
| KR (1) | KR102781208B1 (OSRAM) |
| CN (1) | CN111212852A (OSRAM) |
| AU (2) | AU2018316742B2 (OSRAM) |
| BR (1) | BR112020003306A2 (OSRAM) |
| CA (1) | CA3072998A1 (OSRAM) |
| ES (1) | ES2983651T3 (OSRAM) |
| IL (1) | IL272643A (OSRAM) |
| MX (1) | MX2020001873A (OSRAM) |
| RU (1) | RU2020109544A (OSRAM) |
| SG (1) | SG11202001425TA (OSRAM) |
| WO (1) | WO2019034895A1 (OSRAM) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2983651T3 (es) | 2017-08-18 | 2024-10-24 | Centessa Pharmaceuticals Uk Ltd | Agentes de unión |
| GB201804860D0 (en) | 2018-03-27 | 2018-05-09 | Ultrahuman Two Ltd | CD47 Binding agents |
| GB201906685D0 (en) | 2019-05-13 | 2019-06-26 | Ultrahuman Six Ltd | Activatable protein constructs and uses thereof |
| JP7317148B2 (ja) * | 2019-06-19 | 2023-07-28 | レプ バイオファーマ カンパニー リミテッド | 抗ｃｄ４７抗体およびその使用 |
| EP3999107A1 (en) | 2019-07-16 | 2022-05-25 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
| WO2021061867A1 (en) * | 2019-09-23 | 2021-04-01 | Cytomx Therapeutics, Inc. | Anti-cd47 antibodies, activatable anti-cd47 antibodies, and methods of use thereof |
| US11795223B2 (en) | 2019-10-18 | 2023-10-24 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| MX2022005123A (es) | 2019-10-31 | 2022-05-30 | Forty Seven Inc | Tratamiento basado en anti-cd47 y anti-cd20 para cancer hematologico. |
| MX2022007930A (es) | 2019-12-24 | 2022-08-08 | Carna Biosciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| WO2021142331A1 (en) * | 2020-01-10 | 2021-07-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of genes associated with cardiac muscle disease |
| WO2021142269A1 (en) * | 2020-01-10 | 2021-07-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of genes associated with muscle atrophy |
| BR112022014623A2 (pt) | 2020-02-14 | 2022-09-13 | Jounce Therapeutics Inc | Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos |
| WO2021191870A1 (en) | 2020-03-27 | 2021-09-30 | Dcprime B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| EP4171617A1 (en) | 2020-06-30 | 2023-05-03 | Mendus B.V. | Use of leukemia-derived cells in ovarian cancer vaccines |
| CN111733162A (zh) * | 2020-07-01 | 2020-10-02 | 江苏莱森生物科技研究院有限公司 | 一种经基因修饰的cd47蛋白及其单克隆抗体和应用 |
| WO2022007947A1 (zh) * | 2020-07-10 | 2022-01-13 | 信达生物制药(苏州)有限公司 | 抗cd47抗体或其抗原结合片段和dna甲基化转移酶抑制剂的组合及其用途 |
| KR102757518B1 (ko) * | 2020-12-07 | 2025-01-21 | (주)이노베이션바이오 | Cd47에 특이적인 항체 및 이의 용도 |
| WO2022140659A2 (en) | 2020-12-23 | 2022-06-30 | D-10 Therapeutics, Inc. | Anti-cd47 antibodies and uses thereof |
| US20220305100A1 (en) | 2021-03-12 | 2022-09-29 | Dcprime B.V. | Methods of vaccination and use of cd47 blockade |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| CN112794903B (zh) * | 2021-04-14 | 2021-06-25 | 广州市雷德生物科技有限公司 | 一种特异性结合IFN-γ的抗体及其应用 |
| WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7686086B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリエルコール（ｄｉａｃｙｌｇｌｙｅｒｃｏｌ）キナーゼ調節化合物 |
| WO2023277281A1 (ko) * | 2021-06-30 | 2023-01-05 | (주)이노베이션바이오 | Cd47에 특이적인 인간화 항체 및 이를 포함하는 cd47 관련 질환의 예방 또는 치료용 약학적 조성물 |
| WO2023070353A1 (en) * | 2021-10-27 | 2023-05-04 | Adagene Pte. Ltd. | Anti-cd47 antibodies and methods of use thereof |
| AU2022375782A1 (en) | 2021-10-28 | 2024-05-02 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| PE20241186A1 (es) | 2021-10-29 | 2024-06-03 | Gilead Sciences Inc | Compuestos de cd73 |
| EP4452414A2 (en) | 2021-12-22 | 2024-10-30 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CA3237577A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| IL314395A (en) | 2022-01-31 | 2024-09-01 | Centessa Pharmaceuticals Uk Ltd | Bispecific anti-CD47 and anti-PD-L1 activatable proteins and their uses |
| WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| JP2025509662A (ja) | 2022-03-24 | 2025-04-11 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｒｏｐ－２発現がんを治療するための併用療法 |
| WO2023191117A1 (ko) * | 2022-03-28 | 2023-10-05 | (주)이노베이션바이오 | 친화도가 성숙된 cd47에 특이적인 인간화 항체 |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| CA3260083A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences Inc | CD73 COMPOUNDS |
| CN119677546A (zh) | 2022-07-12 | 2025-03-21 | 吉利德科学公司 | Hiv免疫原性多肽和疫苗及其用途 |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| US20240254118A1 (en) | 2022-12-22 | 2024-08-01 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| AU2024252725A1 (en) | 2023-04-11 | 2025-11-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| CN121079300A (zh) | 2023-04-21 | 2025-12-05 | 吉利德科学公司 | Prmt5抑制剂及其用途 |
| WO2025006720A1 (en) | 2023-06-30 | 2025-01-02 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025096589A1 (en) | 2023-11-03 | 2025-05-08 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| US20250376484A1 (en) | 2024-05-21 | 2025-12-11 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1693385A4 (en) * | 2003-11-11 | 2009-11-04 | Chugai Pharmaceutical Co Ltd | ANTI-CD47 ANTIBODIES HUMANIZED |
| DE102007001370A1 (de) * | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| CN101231382B (zh) | 2008-02-26 | 2010-09-01 | 上海激光等离子体研究所 | 用于啁啾脉冲放大的光谱调制整形装置 |
| HRP20170254T1 (hr) | 2010-05-14 | 2017-04-21 | The Board of Trustees of the Leland Stanford Junior University Office of the General Counsel | Humanizirana i kimerna monoklonska protutijela usmjerena na cd47 |
| EP3578569A1 (en) * | 2012-02-06 | 2019-12-11 | Inhibrx, Inc. | Cd47 antibodies and methods of use thereof |
| US20140140989A1 (en) | 2012-02-06 | 2014-05-22 | Inhibrx Llc | Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof |
| MX2015007446A (es) * | 2012-12-12 | 2015-12-07 | Vasculox Inc | Anticuerpos terapeuticos para cd47. |
| US9221908B2 (en) * | 2012-12-12 | 2015-12-29 | Vasculox, Inc. | Therapeutic CD47 antibodies |
| AU2015350190B2 (en) * | 2014-11-18 | 2021-08-05 | Janssen Pharmaceutica Nv | CD47 antibodies, methods, and uses |
| EP3240569A4 (en) * | 2014-12-30 | 2018-05-30 | Celgene Corporation | Anti-cd47 antibodies and uses thereof |
| US10647756B2 (en) | 2015-05-18 | 2020-05-12 | Pfizer Inc. | Humanized antibodies |
| BR112018005322A2 (pt) | 2015-09-18 | 2018-12-11 | Arch Oncology, Inc. | anticorpo monoclonal ou seu fragmento de ligação a antígenos, composição farmacêutica, anticorpo monoclonal ou seu fragmento de ligação a antígenos para uso, método de tratamento de lesão de isquemia-reperfusão, método de tratamento de câncer em um paciente humano, método de avaliação da expressão de cd47 em células tumorais e/ou imunes usando um anticorpo monoclonal ou seu fragmento de ligação a antígenos |
| EA038880B1 (ru) * | 2016-01-11 | 2021-11-01 | Форти Севен, Инк. | Гуманизированные моноклональные антитела, моноклональные антитела мыши или химерные моноклональные антитела против cd47 |
| ES2983651T3 (es) | 2017-08-18 | 2024-10-24 | Centessa Pharmaceuticals Uk Ltd | Agentes de unión |
| GB201804860D0 (en) | 2018-03-27 | 2018-05-09 | Ultrahuman Two Ltd | CD47 Binding agents |
-
2018
- 2018-08-17 ES ES18759711T patent/ES2983651T3/es active Active
- 2018-08-17 JP JP2020530735A patent/JP7256580B2/ja active Active
- 2018-08-17 WO PCT/GB2018/052347 patent/WO2019034895A1/en not_active Ceased
- 2018-08-17 SG SG11202001425TA patent/SG11202001425TA/en unknown
- 2018-08-17 KR KR1020207007972A patent/KR102781208B1/ko active Active
- 2018-08-17 CA CA3072998A patent/CA3072998A1/en active Pending
- 2018-08-17 EP EP24179206.8A patent/EP4435008A2/en not_active Withdrawn
- 2018-08-17 EP EP18759711.7A patent/EP3668897B1/en active Active
- 2018-08-17 AU AU2018316742A patent/AU2018316742B2/en active Active
- 2018-08-17 MX MX2020001873A patent/MX2020001873A/es unknown
- 2018-08-17 RU RU2020109544A patent/RU2020109544A/ru unknown
- 2018-08-17 CN CN201880066662.5A patent/CN111212852A/zh active Pending
- 2018-08-17 BR BR112020003306-5A patent/BR112020003306A2/pt unknown
-
2019
- 2019-08-19 US US16/543,884 patent/US10683350B2/en active Active
-
2020
- 2020-02-12 IL IL272643A patent/IL272643A/en unknown
- 2020-05-19 US US16/877,938 patent/US11370840B2/en active Active
-
2022
- 2022-06-24 US US17/849,101 patent/US20220332819A1/en not_active Abandoned
-
2023
- 2023-03-27 JP JP2023049983A patent/JP7564274B2/ja active Active
-
2024
- 2024-09-23 US US18/893,023 patent/US20250109202A1/en active Pending
- 2024-09-26 JP JP2024167571A patent/JP2025000787A/ja active Pending
-
2025
- 2025-06-26 AU AU2025204808A patent/AU2025204808A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020531048A5 (OSRAM) | ||
| RU2020109544A (ru) | Связывающие агенты | |
| JP2025000787A5 (OSRAM) | ||
| JP7583707B2 (ja) | 抗ｃｄ４７抗体及びその応用 | |
| US20250059262A1 (en) | Method of preparing ph-dependent antibodies | |
| AU2016328204B2 (en) | Novel anti-mesothelin antibody and composition comprising the same | |
| JP2011518546A5 (OSRAM) | ||
| JPWO2019185717A5 (OSRAM) | ||
| RU2018145852A (ru) | Антитело против lag-3, его антигенсвязывающий фрагмент и их фармацевтическое применение | |
| TW201718657A (zh) | Ｐｄ－ｌ１抗體、其抗原結合片段及其醫藥用途 | |
| WO2014013075A2 (en) | Antibodies to highly conserved targets | |
| JP2020514277A5 (OSRAM) | ||
| JP2012530496A5 (OSRAM) | ||
| JP2010524435A5 (OSRAM) | ||
| JP2020522280A5 (OSRAM) | ||
| RU2019125975A (ru) | Связывающие агенты | |
| JPWO2019224717A5 (OSRAM) | ||
| CA3036912A1 (en) | Antibody specifically binding to pd-1 and functional fragment thereof | |
| JP2020522281A5 (OSRAM) | ||
| JP7679399B2 (ja) | 抗ｆｌｔ３抗体及び組成物 | |
| JP2010509931A5 (OSRAM) | ||
| JP2020505075A5 (OSRAM) | ||
| JP2021512652A5 (OSRAM) | ||
| US20250034273A1 (en) | Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof | |
| JP2019509714A5 (OSRAM) |